Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...
Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.
Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced the expansion of its Scientific Advisory ...
TECregen seed funding supports the development of thymus regeneration biologics designed to restore immune function and ...
San Carlos, California Thursday, January 8, 2026, 13:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback